Halozyme Therapeutics, Inc.HALONASDAQ
Loading
Operating Income Growth Recovery in ProgressRecovering
Percentile Rank62
5Y CAGR-29.0%
Year-over-Year Change
Year-over-year operating income growth rate
5Y CAGR
-29.0%/yr
Long-term compound
Percentile
P62
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 16.74% |
| Q3 2025 | 7.65% |
| Q2 2025 | 43.03% |
| Q1 2025 | -19.35% |
| Q4 2024 | 7.54% |
| Q3 2024 | 39.21% |
| Q2 2024 | 22.71% |
| Q1 2024 | -5.44% |
| Q4 2023 | 14.45% |
| Q3 2023 | -6.54% |
| Q2 2023 | 75.57% |
| Q1 2023 | -27.79% |
| Q4 2022 | -10.54% |
| Q3 2022 | 144.54% |
| Q2 2022 | -54.99% |
| Q1 2022 | 33.85% |
| Q4 2021 | -25.21% |
| Q3 2021 | -18.77% |
| Q2 2021 | 83.40% |
| Q1 2021 | -34.64% |
| Q4 2020 | 92.62% |
| Q3 2020 | 36.35% |
| Q2 2020 | 1017.00% |
| Q1 2020 | 89.95% |
| Q4 2019 | -30.67% |
| Q3 2019 | -75.55% |
| Q2 2019 | -571.24% |
| Q1 2019 | 4277.46% |
| Q4 2018 | 99.72% |
| Q3 2018 | -26.91% |
| Q2 2018 | 15.35% |
| Q1 2018 | -118.83% |
| Q4 2017 | 1459.11% |
| Q3 2017 | 131.70% |
| Q2 2017 | 7.44% |
| Q1 2017 | -21.93% |
| Q4 2016 | 0.74% |
| Q3 2016 | -4.70% |
| Q2 2016 | -34.35% |
| Q1 2016 | -395.86% |